Skip to main content
Jennison Associates logoJennison Associates logo
  • About Us
  • Equity

    • Large Cap Growth
    • Global
    • International
    • Emerging Markets
    • Mid Cap Growth
    • Small Cap Core

    Equity

    • SMid Cap Core
    • Large Cap Value
    • Global Equity Income
    • Rising Dividend

    Thematic Equity

    • Health Sciences
    • Utility Equity
    • Global Infrastructure
    • Global Natural Resources
    • MLP (Master Limited Partnerships)
    • Financial Services

    Thematic Equity

    • Technology Equity
  • Fixed Income
    • Active Long Duration
    • Active Core
    • Active Intermediate
    • Stable Value
    • LDI
  • ESG Overview
    • Integration
    • Proxy Voting
    • Engagement
    • Corporate Citizenship
  • Perspectives
  • Contact Us
aqua blue background with hexagons
Article

Innovation Accelerates Across The Healthcare SectorInnovationAcceleratesAcrossTheHealthcareSector

By Daniel Matviyenko & Debra Netschert — Nov 15, 2022

5 mins

Share
  • Mail
  • LinkedIn
  • Twitter
  • Copy URL

Share

Highlights

  • Innovation is modernizing the healthcare sector, as technology adoption is improving the patient experience, influencing lower costs.
  • Advancements in the ability to diagnose, monitor, and treat diseases with personalized therapeutics is creating a broad set of investment opportunities.
  • Value-based care models are helping patients by shifting the liability to the provider of care, which is encouraging technology investments and driving better outcomes.
  • We believe the current wave of innovation is presenting opportunities for select companies with access to data to demonstrate durable, outsized growth over the next decade, similar to what we observed in the information technology sector from 2010 to 2020.

Healthcare Races toward Tech

Today’s US healthcare system is interconnected. Changes in one industry impact the others. As innovation continues, we expect the sector to resemble the information technology sector over the next decade.

Currently, there are a handful of large tech conglomerates with entrenched competitive advantages. We expect this dynamic to play out in healthcare. Companies that can continue to innovate should benefit. Data will play a crucial function in defining winners. Over time, we expect the healthcare companies that can effectively collect, process, and make sense of data to emerge as the industry’s large conglomerates with established competitive advantages. For example, managed care organizations with hundreds of millions of members are able to collect patient data across different demographics and identify the best treatments for individual patients.

Multiple Ways to Access Therapeutic Breakthroughs and Clinical Research Growth

Advances in DNA sequencing, artificial intelligence, and computational biology in the biotech space have translated into new treatments for chronic diseases such as diabetes and obesity.

There are also early signs that more effective obesity treatments are having a positive impact on cardiovascular disease, which is among the world’s deadliest and most costly conditions to treat. For investors, these advancements are creating new opportunities among select pharmaceutical companies that have the depth of resources—including large balance sheets and sizeable manpower—to capitalize on this enormous market for cardiovascular treatments and prevention.

Additionally, the increase in publicly traded biotech and biopharma companies during the past five years is just one of many ways to gain exposure to potential breakthrough discoveries.

The global experience of COVID-19 highlighted that there has not been nearly enough investment in basic research to develop new treatments. As a result, funding has poured into healthcare innovation since the start of the pandemic. This R&D spending extends to companies along the healthcare supply chain and is creating a much broader investment opportunity set. As one example, the process of analyzing a molecule in a biotech company’s research lab requires, among other things, specialized chemicals and research tools produced by different types of companies.

Opportunities Emerging from Value-Based Care Models

Innovation in healthcare is designed to improve access to care, quality of diagnosis, and patient outcomes, which collectively reduce costs across the healthcare system. At its core, these are the goals and catalysts for innovation in the sector. A shift towards a value-based care model where costs are directly associated with the quality of the result is encouraging technology investments to increase efficiencies. 

Healthcare service providers are guiding this evolution, with access to patient data and developing methods to monitor and optimize the delivery of care.

Contact Us
Jennison Associates

Jennison's investing approach is rooted in our fundamental research and security selection; all of our portfolios are built from the bottom-up, security by security.

Contact Us

  • By Daniel MatviyenkoManaging Director, Jennison Associates
  • By Debra NetschertManaging Director, Jennison Associates
  • About Us

    • About Jennison
    • Firm Profile
    • Our Approach to Investing
    • Contact Us - Form
  • Other Resources

    • Form CRS
Jennison Associates logo
  • Terms & Conditions
  • PGIM Privacy Center
  • Accessibility Help
  • Cookie Preference Center

Jennison Associates LLC. All Rights Reserved.

This website is intended for Institutional and Professional Investors only. All investments involve risk, including the possible loss of capital.

Important Disclosures

Jennison Associates is a registered investment advisor under the U.S. Investment Advisers Act of 1940, as amended and a Prudential Financial company.  Registration as a registered investment adviser does not imply a certain level or skill or training.  Jennison Associates LLC has not been licensed or registered to provide investment services in any jurisdiction outside the United States. Certain investment vehicles are distributed or offered through Prudential Investment Management Services LLC (also a Prudential Financial Company) or other affiliated entities. Additionally, vehicles may not be registered or available for investment in all jurisdictions. 

Please visit https://www.jennison.com/important-disclosuresopens in a new window for important information, including information on non-US jurisdictions 

This web site is not intended as an offer or solicitation with respect to the purchase or sale of any security or other financial instrument or any investment management services. It does not constitute investment advice, should not be used as the basis for any investment decision, and does not purport to provide any legal, tax or accounting advice. This is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence.

Any views or opinions expressed on this website reflect the opinions of Jennison investment professionals at the time they are made and are subject to change.

Your investment objectives, risk tolerance, and liquidity needs must be reviewed before suitable programs can be recommended. Asset allocation and diversification strategies do not assure a profit or protect against loss in declining markets. Investors should consult with their attorney, accountant, and/or tax professional for advice concerning their particular situation.

Please remember that there are inherent risks involved with investing in the markets, and your investments may be worth more or less than your initial investment upon redemption. There is no guarantee that the investment managers’ objectives will be achieved. Further, there is no assurance that any strategies, methods, sectors, or any investment programs herein were or will prove to be profitable, or that any investment recommendations or decisions we make in the future will be profitable for any investor or client. Professional money management is not suitable for all investors.

There is no guarantee our objectives will be met. All investments contain risk, including possible loss of principal. The strategy may vary significantly from the benchmark in several ways including, but not limited to, sector and issuer weightings, portfolio characteristics, and security types.

Information for persons in the United Kingdom and various European Economic Area jurisdictions
In the United Kingdom, information is issued by PGIM Limited with registered office: Grand Buildings, 1-3 Strand, Trafalgar Square, London, WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number 193418). In the European Economic Area (“EEA”), information is issued by PGIM Netherlands B.V. with registered office: Gustav Mahlerlaan 1212, 1081 LA  Amsterdam, The Netherlands. PGIM Netherlands B.V. is authorised by the Autoriteit Financiële Markten (“AFM”) in the Netherlands (Registration number 15003620) and operating on the basis of a European passport. In certain EEA countries, information is, where permitted, presented by PGIM Limited in reliance of provisions, exemptions or licenses available to PGIM Limited under temporary permission arrangements following the exit of the United Kingdom from the European Union. Jennison Associates LLC, PGIM Limited & PGIM Netherlands B.V. are wholly owned subsidiaries of PGIM, Inc. the principal investment management business of Prudential Financial, Inc. (‘PFI’).  PFI of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. These materials are issued by PGIM Limited and/or PGIM Netherlands B.V. to persons who are professional clients as defined  under the rules of the FCA and/or to persons who are professional clients as defined in the relevant local implementation of Directive 2014/65/EU (MiFID II).

Links to third-party sites are intended for informational purposes only and should not be considered investment advice or recommendation to invest. These links do not constitute endorsement or confirm their accuracy, and we are not responsible for any third-party guidelines, security, or accuracy of information.

You are viewing this page in preview mode.

Edit Page